Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

YOU WONT BELIEVE: Benzinga s top ratings upgrades downgrades for april 6 2022 - You Need To See This

Upgrades

According to Morgan Stanley, the prior rating for Royalty Pharma PLC (NASDAQ:RPRX) was changed from Equal-Weight to Overweight. In the fourth quarter, Royalty Pharma showed an EPS of $0.80, compared to $0.27 from the year-ago quarter. The current stock performance of Royalty Pharma shows a 52-week-high of $47.10 and a 52-week-low of $34.86. Moreover, at the end of the last trading period, the closing price was at $39.84.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.